PREVALENCE AND ISOTYPE DISTRIBUTION OF ANTIPHOSPHOLIPID ANTIBODIES IN UNSELECTED CHILEAN PATIENTS WITH VENOUS AND ARTERIAL THROMBOSIS.

Saved in:

Bibliographic Details
Title:	PREVALENCE AND ISOTYPE DISTRIBUTION OF ANTIPHOSPHOLIPID ANTIBODIES IN UNSELECTED CHILEAN PATIENTS WITH VENOUS AND ARTERIAL THROMBOSIS.
Authors:	Palomo, Iván¹ ipalomo@utalca.cl, Pereira, Jaime², Alarcón, Marcelo¹, Vásquez, Marcela¹, Pinochet, Carmen³, Vélez, María T.³, Sandoval, Jorge³, Icaza, Gloria⁴, Pierangeli, Silvia⁵
Source:	Revista VacciMonitor (Vacunología y Temas Afines). Oct2002, Vol. 11 Issue 4, p1. 1p.
Subjects:	PHOSPHOLIPID antibodies, THROMBOSIS, GLYCOPROTEINS, DISEASE prevalence
Geographic Terms:	CHILE
Abstract:	Introduction. Antiphospholipid Antibodies (aPL) has been associated with thrombotic events. The objective of this study was to investigate the prevalence of aPL in a group of Chilean patients with venous and arterial thrombosis. Patients and Methods. Two hundred twenty six patients with venous and arterial thrombosis and 95 healthy controls were included in this study. Anticardiolipin (aCL), Anti-β2Glycoprotein I (anti-β2GPI) and Antiprothrombin (aPT) antibodies, were determined by ELISA using "in-house" assays. Results. Eighty eight out of 226 (38.9%) patients with thrombosis had some type of aPL. The prevalence of aCL, anti-β2GPI and aPT in patients with TV y TA, and in control group, shows in the following table: Twelve patients (5.3%) were positive for mixture of aPL. IgG, IgM and IgA isotypes were observed in aCL, Anti-β2GPI and aPT antibodies. Twenty four out of 78 (30.8%) patients with deep venous thrombosis, 2/14 (14.3%) with retinal venous thrombosis 17/68 (25.0%) with ischemic stroke and 14/66 (21.2%) with acute myocardial infarction, were positive for aCL antibodies. Anti-β2GPI and aPT antibodies were also present in these groups although in minor proportion. Conclusion. Our results show an important prevalence of aPL in patients with thrombosis, and aCL and aPT seem to be a risk factor of venous and arterial thrombosis. [ABSTRACT FROM AUTHOR]
	Copyright of Revista VacciMonitor (Vacunología y Temas Afines) is the property of Vacunas Finlay S.A. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Introduction. Antiphospholipid Antibodies (aPL) has been associated with thrombotic events. The objective of this study was to investigate the prevalence of aPL in a group of Chilean patients with venous and arterial thrombosis. Patients and Methods. Two hundred twenty six patients with venous and arterial thrombosis and 95 healthy controls were included in this study. Anticardiolipin (aCL), Anti-β2Glycoprotein I (anti-β2GPI) and Antiprothrombin (aPT) antibodies, were determined by ELISA using "in-house" assays. Results. Eighty eight out of 226 (38.9%) patients with thrombosis had some type of aPL. The prevalence of aCL, anti-β2GPI and aPT in patients with TV y TA, and in control group, shows in the following table: Twelve patients (5.3%) were positive for mixture of aPL. IgG, IgM and IgA isotypes were observed in aCL, Anti-β2GPI and aPT antibodies. Twenty four out of 78 (30.8%) patients with deep venous thrombosis, 2/14 (14.3%) with retinal venous thrombosis 17/68 (25.0%) with ischemic stroke and 14/66 (21.2%) with acute myocardial infarction, were positive for aCL antibodies. Anti-β2GPI and aPT antibodies were also present in these groups although in minor proportion. Conclusion. Our results show an important prevalence of aPL in patients with thrombosis, and aCL and aPT seem to be a risk factor of venous and arterial thrombosis. [ABSTRACT FROM AUTHOR]
ISSN:	1025028X